Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Patient characteristics

From: IFN-γ production in response to in vitro stimulation with collagen type II in rheumatoid arthritis is associated with HLA-DRB1*0401 and HLA-DQ8

  Number Age Sex   Disease   Erosive
  of subjects (years) (F/total)   duration (years) CRP disease
All patients 45 55 34/45   10 15 27/42
   (23–86) (76%)   (0.5–30) (0–95) (64%)
Patients with   54 15/19   8 10 12/18
high anti-CII levels 19 (31–86) (79%)   (0.5–30) (0–95) (67%)
Patients with low 26 55 19/26   12.5 20 15/24
anti-CII levels   (23–78) (73%)   (2.0–30) (0–62) (63%)
Healthy controls 25 51 22/25   ND
   (36–61) (88%)     
  Number of Number of    Mean daily   
  swollen tender NSAID Steroid prednisolone MTX DMARD
  joints joints therapy therapy dosage therapy therapy
All patients 2 4 26/42 13/42 2.0 13/42 30/42
  (0–17) (0–17) (62%) (31%)   (31%) (71%)
Patients with 9 6 10/18 4/18 1.1 5/18 9/18
high anti-CII levels (0–17) (0–17) (56%) (22%)   (28%) (50%)
Patients with low 2 3 16/24 9/24 /2.7 8/24 21/24
anti-CII levels (0-15) (0–16) (67%) (38%)   (33%) (88%)
Healthy controls
  1. Data are given as median values and ranges for the various groups. Daily prednisolone dosages are presented as mean values in mg. Disease Modifying antirheumatic drugs (DMARDs) include sulfasalazin (0/18 high anti-CII patients treated, 6/24 low anti-CII patients treated,), cyklosporine (1/18 high anti-CII, 1/24 low anti-CII), Reumacon (a podophyllin derivative, 1/18 high anti-CII, 1/24 low anti-CII), chloroquine (0/18 high anti-CII, 2/24 low anti-CII), aurathiomalase (0/18 high anti-CII, 3/24 low anti-CII), auranofin (1/18 high anti-CII, 0/24 low anti-CII) and azatioprin (1/18 high Anti-CII, 1/24 low anti-CII). Figures for sex distribution, erosiveness and medications are given both as fraction of number positive/number Investigated, and as percentage. Data on erosive disease are based on X-ray evaluations. Patient charts were not available for three patients, one With high anti-CII levels and two with low anti-CII levels. F, female; CRP, C-reactive protein; NSAID, nonsteroidal anti-inflammatory drug; MTX, Methotrexate; ND, not done; CII, collagen type II.